SHCBP1 was found correlating with trastuzumab sensitivity in patients who received trastuzumab-based therapy, and SHCBP1 deletion rendered gastric cancer sensitive to trastuzumab, implying that SHCBP1 contributed to trastuzumab sensitivity and was targeted therapeutically. Here, SHCBP1 is linked to gastric cancer.